- Positive Phase 1 data were previously presented in an oral session at ASCO 2026

- Emi-Le received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the proposed treatment of patients with locally advanced, recurrent or metastatic ACC with solid histology or high-grade transformation

BOSTON, Oct. 19, 2026 /PRNewswire/ -- Servier today announced the first patients have been dosed in the pivotal Phase 2 cohort (EMBLEM-1) of a Phase 1/2 study of Emiltatug Ledadotin (Emi-Le) in solid tumors. EMBLEM-1 is evaluating the antitumor activity and safety of Emi-Le, an investigational antibody drug conjugate (ADC) directed against B7-H4, in aggressive adenoid cystic carcinoma (ACC).

"Dosing these first patients marks an important step in advancing Emi-Le as a potential targeted treatment for ACC, a difficult-to-treat cancer with no FDA-approved systemic treatment options," said Becky Martin, PhD, Chief of Medical, Servier Pharmaceuticals. "This milestone also underscores the momentum of Servier's growing oncology portfolio and our commitment to bringing scientific rigor and meaningful innovation to rare cancers where patients face significant unmet need. We look forward to sharing these data with the scientific community."

The primary endpoint is objective response rate (ORR)—defined as the percentage of patients who achieve a best overall response of confirmed complete response (CR) or partial response (PR)— per RECIST 1.1.

The initiation of EMBLEM-1 is supported by clinical data from a Phase 1 analysis of Emi-Le, which demonstrated a differentiated safety profile and were presented in an oral session at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.

Earlier this year, Emi-Le received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the proposed treatment of patients with locally advanced, recurrent or metastatic ACC with solid histology or high-grade transformation.

The EMBLEM-1 cohort is currently enrolling (NCT05377996). Additional details regarding the clinical trial can be found here.

Media contact 

Darby Malkin: [email protected] 

About Emi-Le

Emi-Le is an investigational B7-H4-directed Dolasynthen antibody drug conjugate (ADC) with a drug-to-antibody ratio (DAR) of 6 and a proprietary auristatin-F HPA payload designed to provide a controlled bystander effect as demonstrated in preclinical models. Emi-Le is under evaluation in an ongoing Phase 1/2 clinical trial and has not been approved by the FDA, and its safety and effectiveness have not been established. The U.S. Food and Drug Administration has granted Fast Track designations to Emi-Le for the treatment of 1) adult patients with advanced or metastatic triple-negative breast cancer, and 2) advanced or metastatic HER2 low / HER2 negative breast cancer post-topo-1 ADC (including TNBC and certain HR+ breast cancers). It has also received Breakthrough Designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma with solid histology or high-grade transformation. For more information about the trial, visit clinicaltrials.gov (NCT05377996).

About Adenoid Cystic Carcinoma

Adenoid cystic carcinoma (ACC) occurs in the secretory glands, typically in the head and neck, but also in other areas of the body. Globally, more than 200,000 people have ACC. It is diagnosed in roughly four per one million people annually and does not discriminate by ethnicity or lifestyle factors. Today there are no approved or preferred systemic therapies to treat advanced or metastatic ACC; most people are treated with surgery or radiation, but the disease recurs in 50 percent of cases, often becoming more aggressive with metastases in distant areas of the body.1

About Servier in Oncology

Servier is a global leader in oncology, governed by a non-profit foundation. Servier approaches innovation with a long-term vision, free of influence from fiduciary responsibilities. 

Servier invests close to 20% of revenue from brand-name medicines in R&D each year. Servier aspires to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its progression. Servier believes we can serve more people by helping the right patients find the right treatment, at the right time.

Servier takes a One Innovation Engine approach to R&D and is actively seeking alliances, partnerships and acquisitions at various stages of the portfolio.

For more information about working with Servier to bring the promise of tomorrow to the patients it serves, visit Servier.com and Servier.us.

Disclosures

This release contains general information about the Servier Group and its entities (hereinafter "Servier and its Affiliates") and is intended for informational purposes only. The information is thought to be reliable; however, Servier and its Affiliates make no representation as to the accuracy or completeness of the information contained herein or otherwise provided and accept no responsibility or liability, in contract, in tort, in negligence, or otherwise, should the information be found to be inaccurate or incomplete in any respect.

Servier and its Affiliates are not acting as an advisor to the recipient of this information, and the ultimate decision to proceed with any transaction rests solely with the recipient of this information. Therefore, prior to entering into any proposed transaction, the recipient of this information should determine, without reliance upon Servier or its Affiliates, the economic risks and merits, as well as the legal, tax, and accounting characterizations and consequences, of the transaction and that it is able to assume these risks.

This statement also contains forward-looking statements that are subject to varying levels of uncertainty and risk. Investigational new drugs and indications are subject to further scientific and medical review and regulatory approval. They are not approved for use by the FDA.

Any reliance placed on this document is done entirely at the risk of the person placing such reliance. The information contained in this document is neither an offer to sell nor the solicitation of an offer to enter into a transaction.

The content of this document is a summary only, is not complete, and does not include all material information about Servier and its Affiliates, including potential conflicts of interest.

To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates disclaim all representations, warranties, conditions and guarantees, whether express, implied, statutory or of other kind, nor does it accept any duty to any person, in connection with this document. Without prejudice to the generality of the foregoing, Servier and its Affiliates do not warrant or represent that the information or opinions contained in this document is accurate or complete.

To the maximum extent permitted by applicable laws and regulations, Servier and its Affiliates shall not be liable for any loss, damage or expense whatsoever, whether direct or indirect, howsoever arising, whether in contract, tort (including negligence), strict liability or otherwise, for direct, indirect, incidental, consequential, punitive or special damages arising out of or in connection with this document, including (without limitation) any course of action taken on the basis of the same. The estimates, strategies, and views expressed in this document are based upon past or current data and information and are subject to change without notice.

References

1 Adenoid Cystic Carcinoma Research Foundation. Accessed May 2026.

SOURCE Servier Pharmaceuticals

Share this article

- Students across the U.S. can apply for $3,000 scholarships for eligible technical education and training programs

- Schneider Electric's additional $100,000 investment supports training for careers in buildings, energy and critical infrastructure

ATLANTA, Oct. 19, 2026 /PRNewswire/ -- Schneider Electric, a global energy technology leader, and SKILLED Nation, an organization that expands access to education and training for high-demand skilled careers, are inviting students across the United States to apply for $3,000 scholarships through the Schneider Electric SKILLED Scholarship Program.

As investment in electrification, building modernization and critical infrastructure accelerates across the U.S., developing the skilled workforce needed to support these industries has become an increasingly important priority for America's energy future. To help address this challenge, Schneider Electric and SKILLED Nation are announcing an additional $100,000 in scholarships for technical education and training nationwide.

Now in its fourth year, the Schneider Electric SKILLED Scholarship Program has received more than $300,000 in funding from Schneider Electric to help students pursue technical careers across America's buildings, energy systems and critical infrastructure. The scholarships help fund postsecondary education and training that can lead to careers in building automation, energy management, HVAC, electrical systems, facilities engineering and maintenance, green building and sustainability, security and related technical fields.

"For us, the real measure of this program is where it can take students," said Alvin Townley, Founding Executive Director of SKILLED Nation. "These scholarships help students pay for the training to gain practical skills for careers installing, operating and maintaining the systems that power our buildings, energy infrastructure and communities."

Developing Technical Talent for Energy and Infrastructure

As buildings and energy infrastructure become more electrified, connected and intelligent, developing specialized technical skills is essential to helping customers realize the full value of modernization.

"The future of American energy infrastructure will be defined as much by the talent behind it as the technology powering it," said Chris Collins, Senior Vice President, Secure Power, North America, Schneider Electric. "At Schneider Electric, we see workforce development as a strategic investment in our customers' competitiveness, our nation's energy resilience and the next generation of American industry. Our partnership with SKILLED Nation helps students access the technical education and training to build that future."

Building on 190 years of innovation globally and more than 135 years of operations in the U.S., Schneider Electric is investing in the technology and talent essential to modernizing energy infrastructure. Since 2009, Schneider Electric has trained more than 1 million young people across more than 60 countries, helping them build practical skills in energy management. Through its Impact 2030 sustainability ambition, the company aims to equip more than 3 million young people with skills in electrification and sustainability. The SKILLED Nation partnership extends that global commitment in the U.S., creating pathways to technical careers that will help shape the future of American industry.

Launched in 2022 with scholarships in New York and New Jersey, Schneider Electric's partnership with SKILLED Nation later expanded to Boston, Dallas and other communities. The scholarships are open to qualifying students nationwide.

How to Apply for a Scholarship

The deadline to apply is Tuesday, Nov. 10. To apply, visit https://skilled-nation.org/partner/sescholarship.

Schneider Electric employees, their spouses and their dependents are not eligible to apply.

About SKILLED Nation

SKILLED Nation partners with corporations, foundations and philanthropic leaders to expand access to education and training for high-demand skilled careers. Through scholarship programs and workforce partnerships, SKILLED Nation helps individuals pursue skills and credentials that increase economic mobility while helping employers build the skilled workforce they need.

Learn more at www.skilled-nation.org.

About Schneider Electric

Schneider Electric is a global energy technology leader, driving efficiency and sustainability by electrifying, automating, and digitalizing industries, businesses, and homes. Its technologies enable buildings, data centers, factories, infrastructure, and grids to operate as open, interconnected ecosystems, enhancing performance, resilience, and sustainability. The portfolio includes intelligent devices, software-defined architectures, AI-powered systems, digital services, and expert advisory. With 160,000 employees and 1 million partners in over 100 countries, Schneider Electric is consistently ranked among the world's most sustainable companies. 

SOURCE Schneider Electric

Share this article

Hypershell Named to TIME's 2026 Best Inventions

Redefining the boundaries of human performance, the Hypershell X Ultra S earns top recognition from TIME

- TIME Best Inventions 2026: Hypershell X Ultra S has been named to TIME's Best Inventions of 2026 in the Sports & Fitness category, recognizing its groundbreaking innovation and contribution to advancing the future of human mobility.

- A Year of Industry Recognition: The TIME recognition builds on a standout year for Hypershell, with its AI-powered consumer exoskeletons earning accolades from leading publications including Fast Company and Tom's Guide, among others.

- Redefining Human Performance: At the forefront of wearable mobility innovation, Hypershell's award-winning X Series combines a lightweight, foldable 1.7 kg design with technologies engineered to reduce physical exertion. The series is the world's first consumer exoskeleton lineup to have its performance verified by both TÜV Rheinland and SGS.

HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Hypershell, the world's leading consumer exoskeleton brand, is excited to announce that X Ultra S has been selected for TIME's 2026 Best Inventions list in the Sports & Fitness category. The recognition underscores Hypershell's continued innovation in AI-powered wearable robotics and its mission to expand human mobility through technology.

For 26 years, TIME has highlighted the world's most impactful new products and ideas through its annual Best Inventions issue. Each year, innovations across rapidly evolving fields are evaluated against key criteria such as originality, efficacy, ambition, and real-world impact.

"It's an incredible honor to have Hypershell X Ultra S recognized among TIME's Best Inventions of 2026. Exoskeletons are no longer science fiction. They're helping everyday people go farther than they thought possible," said Kelvin Sun, founder and CEO of Hypershell.

Highlighting the growing demand in a global exoskeleton market projected to reach $1.79 billion by 2033, TIME commended Hypershell X Ultra S for overcoming a common industry hurdle: the rigid feel of traditional robotic wearables. X Ultra S addresses this with its groundbreaking HyperIntuition™ motion control algorithm, which analyzes and anticipates a user's movements in real time to allow for remarkably fluid motion.

"X Ultra S brings AI and precision robotics together with advanced wearable technology to take the strain off your legs and knees, lighten every climb, and help you go farther with less fatigue," Kelvin added. "Powered by HyperIntuition™, X Ultra S delivers intuitive, seamless assistance that moves naturally with the wearer, making it feel more like an extension of the body than a rigid external device."

Key features of the Hypershell X Ultra S include:

- The flagship model X Ultra S is built for mixed terrain and demanding outdoor conditions. The revolutionary HyperIntuition™ motion control algorithm analyzes user movements in real-time for seamless, natural assistance without the rigidity of traditional exoskeletons.

- The ultra-lightweight, 1.7 kg foldable device is verified by Germany's TÜV Rheinland to achieve 97.5% gait synchronization.

- Powered by a 1000W motor system that responds to the user's stride in just 0.31 seconds, SGS certification proves the exoskeleton decreases average oxygen consumption by up to 39.2% and lowers average heart rate by up to 42.7%.

- Built with an aerospace-grade titanium alloy chassis to withstand the elements from -20°C to 60°C, the exoskeleton offers adventurers hands-free control via the Hypershell+ app and Apple Watch to effortlessly amplify their natural exploration.

The TIME recognition further adds to a remarkable year for Hypershell, following honors from Fast Company's 2026 Next Big Things in Tech, Fast Company's World Changing Ideas Awards and the Tom's Guide Fitness Awards 2026. Together, these recognitions reflect growing industry acknowledgment of Hypershell's role in bringing consumer exoskeleton technology closer to mainstream adoption.

The full Hypershell X Series lineup is available now at Hypershell.com and on Amazon.

All product specifications are subject to the information published on the official Hypershell website.

About Hypershell

Founded in 2021, Hypershell is a world-leading exoskeleton company focused on empowering human exploration. Its intelligent exoskeletons adapt in real time to terrain, activity, and intention, making movement lighter and more natural. With SGS-certified and TÜV Rheinland-verified performance and tens of thousands of units sold across 70+ countries, Hypershell enhances, not replaces, human ability – shaping a future where wearable robotics become as essential as backpacks for exploration, work, and play.

SOURCE Hypershell

Share this article

Calamos Extends Autocallable Leadership through CAYN--World's First Indexed Least-Of Autocallable Income ETF

- Calamos continues to innovate in autocallable ETFs with an indexed approach to the popular "least-of" (also known as "worst-of") autocallable income structure—expanding upon the broadest line of autocallable ETFs in the world.

- CAYN links income payments and principal repayment to the weakest performer among SPY, QQQ and IWM, via a weekly ladder of synthetic notes, each with a three-year maturity, 30% downside coupon and principal barriers, and a coupon-memory feature.

- CAYN seeks enhanced tax efficiency, improved coupon reliability and greater principal preservation relative to single notes and non-indexed worst-of ETFs.

METRO CHICAGO, Ill., Oct. 19, 2026 /PRNewswire/ -- John Koudounis, President and CEO of Calamos, a leading alternatives manager, today announced the planned launch of the Calamos Least-Of Autocallable Income ETF (CAYN) on October 26, 2026. Calamos developed CAYN with MerQube and Citibank as the world's first indexed approach to autocallable income tied to the popular "worst-of" structured note strategy.

"The autocallable ETF category is taking off, with growing investor demand for multiple strategies. Our planned launch of CAYN further demonstrates Calamos' leadership in the autocallable ETF space that we created with CAIE in 2025," said John Koudounis, President and CEO of Calamos. "We're excited to improve the least-of strategy and to soon offer another powerful product for income-oriented investors seeking higher coupons from equities."

Calamos was named Asset Manager of the Year (AUM between $25 billion and $500 billion) at the 2026 MMI/Barron's Industry Awards. Its Autocallable ETF lineup has also received multiple awards alone in 2026, including Investment Product Innovation (MMI/Barron's) and, from SRP Americas, Best Structured ETF Solution and ETF Innovation of the Year.1

"For investors looking for a worst-of autocallable solution, we've built the first indexed least-of autocallable strategy, designed to bring tax-efficiency, liquidity, and a degree of principal preservation and coupon reliability to the most popular product type in the legacy autocallable yield note market," said Matt Kaufman, Global Head of ETFs at Calamos. "CAYN will use the same 'Structured ETF' framework that has powered the success of CAIE, CAIQ and CAGE—trading an index on swap, an innovation that the worst-of autocallable strategy has never seen before in the ETF space. We look forward to expanding the Calamos Autocallable ETF family for investors seeking one of the most popular forms of autocallable income via the ETF wrapper."

About the ETF

CAYN is designed to seek high, tax-efficient income by tying income and principal repayment to the weakest performer among three ETFs representing large-cap stocks (SPY), growth stocks (QQQ) and small-cap stocks (IWM). Rather than investing in a single worst-of autocallable note ("note") or a non-indexed worst-of autocallable ETF, CAYN provides exposure to a weekly laddered index of at least 52 synthetic worst-of autocallable notes, each with a three-year maturity and 30% downside coupon and principal barriers. When a note in the portfolio is called away, the principal is returned to the fund and reinvested in a new note with the same terms. Each note's three-year term is designed to allow more time to recover from market declines, seeking to reduce the risk of principal impairment.

CAYN's index also features a "memory" mechanism that stores missed coupons and pays them once the worst-performing constituent is back above the coupon barrier. Calamos will trade the MerQube US Equity Least-Of Autocallable Index (MQAUTOWL) on swap. CAYN intends to take a multi-counterparty approach, with Citibank as the primary counterparty.

To learn more, see the filing on SEC EDGAR here, and visit Autocallable ETFs | Calamos Investments

About Calamos

Calamos is a diversified global investment firm, headquartered in the Chicago metropolitan area, offering innovative investment strategies, including autocallables, Bitcoin, liquid alternatives, convertible, equity, fixed income, multi-asset, hedge fund, private credit, and private equity. With more than $53 billion in AUM, including more than $26 billion in liquid alternatives assets as of September 30, 2026, the firm offers strategies through ETFs, mutual funds, closed-end funds, interval funds, UCITS funds and separately managed portfolios. Clients include financial advisors, wealth management platforms, pension funds, foundations & endowments, and individuals, globally. For more information, visit us on LinkedIn, X (formerly Twitter), Instagram (@calamos_investments), or at www.calamos.com

Before investing, carefully consider the Fund's investment objectives, risks, charges and expenses. Please see the prospectus and summary prospectus containing this and other information which can be obtained by calling 1-866-363-9219. Read it carefully before investing.

An investment in the Fund is subject to risks, and you could lose money on your investment in the Fund. There can be no assurance that the Fund will achieve its investment objective. Your investment in the Fund is not a deposit in a bank and is not insured or guaranteed by the Federal Deposit Insurance Corporation (FDIC) or any other government agency. The risks associated with an investment in the Fund can increase during times of significant market volatility. The Fund also has specific principal risks, which are described below. More detailed information regarding these risks can be found in the Fund's prospectus. The principal risks of investing in the Calamos Least-of Autocallable Income Fund include: authorized participant concentration risk, autocallable structure risk, contingent income risk, early redemption risk, barrier risk, box spread risk, calculation methodology risk, cash holdings risk, correlation risk, costs of buying and selling fund shares, counterparty risk, credit risk, derivatives risk, equity securities risk, FLEX options risk, index risk, interest rate risk, investment in a subsidiary, laddered portfolio risk, liquidity risk, market maker risk, market risk, new fund risk, non-diversification risk, other investment companies risk, premium-discount risk, secondary market trading risk, swap arrangement risk, swap agreement termination risk, tax risk, trading issues risk, valuation risk.

Autocallable Structure Risk — The Fund's returns are correlated to the performance of a theoretical portfolio of Autocallables reflected by the Autocallable Index. Autocallable notes have specific structural features that may be unfamiliar to many investors.

Contingent Income Risk — Coupon payments from the Autocallables are not guaranteed and will not be made if the least performing Constituent falls below the Coupon Barrier on Observation Dates. This means the Fund may generate significantly less income than anticipated during market downturns.

Barrier Risk — If the least-performing Constituent falls below the Maturity Barrier at the maturity of an Autocallable in the Index Portfolio, that portion of the Index Portfolio will be fully exposed to the negative performance of the least-performing Constituent from its initial level. This conditional protection creates a binary outcome that can result in sudden, significant losses if barriers are breached.

Citibank N.A. acts as the Primary Swap Provider and Citigroup Global Markets Inc. (together, "Citi") acts as the Authorized Participant with respect to CAYN. Citi has not participated in the preparation of this presentation and makes no representation or warranty, express or implied, regarding the accuracy or completeness of any information contained herein. Citi does not sponsor, endorse, sell or promote CAYN and makes no representation or warranty, express or implied, regarding the advisability of investing in securities generally or in CAYN particularly. Citi has no obligation to take the needs of CAYN or its investors into consideration in acting as the primary swap provider for CAYN, may engage in trading and hedging activities (including in the reference assets) for its own account that could affect the value of CAYN, and shall have no liability in connection with the administration, marketing or trading of CAYN.

1Selection criteria and methodologies for awards: Impact Awards | Money Management Institute, Home - SRP Americas Awards 2026

SOURCE Calamos Investments

Share this article

BEVERLY, Mass., Oct. 19, 2026 /PRNewswire/ -- DataOne Software, a Dominion Enterprises company and a leading provider of automotive data and software solutions, today announced the availability of Massachusetts vehicle registration and sales data within its Cross-Sell Reports market intelligence solutions for dealers. Cross-Sell Reports, including the Cross-Sell Interactive web interface, provide auto dealers with unparalleled insight into local market trends, giving them a competitive edge in reaching new customers and expanding market share. The addition of Massachusetts data to Cross-Sell Reports expands coverage to 40 states.

"As of today, Massachusetts dealers can now access a current, accurate view of new and used vehicle transactions within their market area," explains David Wall, DataOne head of Cross-Sell Reports. "Localized data, in easy-to-interpret views, are an incredible advantage to dealers who want to spot trends early and make decisions based on accurate market intelligence. We are thrilled to be bringing this capability not only to Massachusetts dealers but also to dealerships in other New England states whose target markets cross into Massachusetts."

On average, over 3.8 million vehicle transactions are processed monthly for inclusion in Cross-Sell Reports, covering new and used dealer transactions across 40 states, all sourced from official state DMV records. Each dealer subscription is configured to the dealer's unique market area and provides:

- Competitive market share analysis by dealership, make, and model

- ZIP code-level heat mapping to identify buyer activity and emerging markets

- Inventory trend analysis to inform stocking decisions by segment and season

- Interactive dashboards with drill-down reporting — no analytics infrastructure required

"We know dealers trust Cross-Sell Reports for critical market insight, and for those insights to be delivered with industry-leading speed and timeliness," says Jake Maki, DataOne President. "With the addition of Massachusetts state coverage, we continue to expand our coverage providing more dealers with the most immediate, accurate market intelligence available."

Since welcoming the Cross-Sell brand into DataOne earlier this year, DataOne has accelerated efforts to expand state coverage of vehicle registration and sales data. In addition to Massachusetts, Cross-Sell Reports recently added Mississippi, Kansas and Georgia to its coverage.

"Our goal is to make DataOne the most accurate and comprehensive source of vehicle registration and sales data, however customers choose to use it," says Maki. "For a dealer, that might be a Cross-Sell Interactive dashboard tuned to their local market. For other customers looking to license the data, it might be multi-state data integrated directly into their own platforms. Every new state we add makes both more valuable."

In addition to Cross-Sell Reports and Cross-Sell Interactive, DataOne offers Vehicle Registration and Sales Data for licensing via API or FTP data feed, with coverage configurable by state or region.

For general information about DataOne solutions, contact DataOne at 877.438.8467, e-mail [email protected] or visit dataonesoftware.com. For specific information about Cross-Sell Reports or Cross-Sell Interactive for dealers, visit Cross-Sell Reports.

About DataOne Software

DataOne Software (www.dataonesoftware.com) is a premier automotive data source providing the data and software solutions needed to power modern businesses across all segments of the automotive industry. DataOne's comprehensive data solutions cover everything from VIN decoding and vehicle descriptions to specifications, optional equipment, and market pricing. With the acquisition of Cross-Sell in 2026, DataOne has expanded our product offering to include PII-free vehicle sales and registration data. Our high-quality solutions are delivered with industry-leading support, making them easy to integrate and scale.

Media Contact

Alice Fackre, Product and Brand Marketing Manager

Email: alice[email protected]

Phone: (978) 473-9097

SOURCE DataOne Software

Share this article

Broader MedTech industry at turning point, seeking positioning to optimize portfolios, differentiate technology and improve R&D

- Innovation drives increased dealmaking and R&D investment: MedTech saw a resurgence in deal size with M&A value up 160% in the first half of 2026 vs. the same period in 2025, reflecting investments in next-generation technologies, including AI-enabled diagnostics, robotics, structural heart, diabetes care and minimally invasive therapies.

- AI is reshaping the future of value creation: AI integration in MedTech is unlocking new business opportunities and scalable value creation, alongside a record and growing number of FDA-authorized AI-enabled devices.

- Industry growth is expanding into alternative care settings: MedTech is increasingly moving beyond traditional care settings and capturing growth in alternative care markets, particularly the rapidly expanding ambulatory surgery center (ASC) market and direct to consumer/patient.

NEW YORK, Oct. 19, 2026 /PRNewswire/ -- The 20th edition of the Ernst & Young LLP (EY US) Pulse of the MedTech Industry report finds that the global medical technology (MedTech) industry is at a turning point. Following a period of record-setting growth and investment across the US and Europe, the sector finds itself at a revenue high point, even amid challenges, including negative investor sentiment and persistent global trade and supply chain uncertainties.

Despite a challenging operating environment, the MedTech industry saw sustained growth in 2025, reaching approximately US$650 billion in revenue and representing growth of 11%, and continued to demonstrate top-line performance in the first half of 2026, generating $325 billion in revenue, a 7.1% increase compared with the same time period in 2025. Therapeutic devices led industry growth, followed by non-imaging diagnostic, imaging, and lab equipment and tools. However, growth was highly concentrated among commercial leaders, highlighting a widening performance gap across the industry.

"MedTech has rebounded from YTD June lows and has underperformed the broader markets in 2026. The sector has continued to demonstrate resiliency, with record revenue financing and strong M&A activity setting the stage for a bright future," says John Babitt, EY Global MedTech Leader. "The broader sector players are at a turning point where discipline is essential to convert innovation into profitable growth."

Other key findings include:

- MedTech financing reached a record US$63 billion for the year ended June 30, 2026, up 87% year over year – the highest seen in the last decade. Together, initial public offerings and debt accounted for around 80% of total capital raised, indicating that recovery has been driven primarily by public-market reopening and strategic balance sheet financing rather than broad-based funding strength.

- MedTech M&A reached its highest level in more than a decade, with total disclosed deal value surging to roughly US$130 billion. However, this recovery was driven by a limited number of blockbuster transactions.

- Innovation remains at the core of MedTech's heartbeat, with growth largely driven by a breakout group of high-performing, high-differentiation, high-innovation strategic leaders. Companies that delivered both high R&D productivity and EBIT margin expansion generated an average total shareholder return of approximately 13.8%.

- AI in MedTech is observing a transformation, with intelligence being deeply embedded into devices and the care pathways around them. Hardware design, clinical evidence and manufacturing quality will remain fundamental and are increasingly being complemented by the quality of the algorithms, data and digital services surrounding the product.

- Venture capital fundraising remained resilient in 2026, with overall activity skewed toward earlier-stage innovation, highlighting improved investment activity and continued investor conviction in differentiated technologies addressing significant unmet clinical needs.

"MedTech is entering a new era of growth, and today's challenges are the catalyst for the industry's next transformations," says Diana Hoff, EY Americas Life Sciences Sector Leader. "As companies navigate margin pressure, supply chain risk and global trade uncertainty, the leaders of the next decade will be those that embrace AI, make more deliberate portfolio choices and build productive, resilient operating models that turn innovation into sustained growth and value."

Looking ahead, MedTechs that maintain innovation while also building conviction across capital allocation and portfolio optimization will be best positioned to set the pace of the pulse of the industry in the years to come.

To read Pulse of the MedTech Industry, please visit https://www.ey.com/en_us/life-sciences/pulse-of-medtech-industry-outlook?WT.mc_id=14001805&AA.tsrc=pr.

About EY

EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets.

Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow.

EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions.

Fueled by sector insights, a globally connected, multidisciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories.

All in to shape the future with confidence.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

About EY Consumer and Health

The rise of the empowered consumer, coupled with technology advancements and the emergence of digitally focused entrants, is changing every aspect of health and care delivery. To retain relevancy in today's digitally focused, data-infused ecosystem, all participants in healthcare today must rethink their business practices, including capital strategy, partnering and the creation of patient-centric operating models.

The EY Consumer and Health architecture brings together a worldwide network of 34,000 professionals to build data-centric approaches to customer engagement and improved outcomes. We help our clients deliver on their strategic goals, design optimized operating models and form the right partnerships so they may thrive today and succeed in the health systems of tomorrow. We work across the ecosystem to understand the implications of today's trends, proactively finding solutions to business issues, and to seize the upside of disruption in this transformative age.

Media contact: Carol Piering, [email protected]

SOURCE EY

Share this article

Clinical ink Announces Strategic Investment from Ardan Equity and GI Partners to Accelerate Next Phase of Growth

Ardan and GI to bring deep, complementary domain expertise across life sciences and healthcare technology and partner with management to further accelerate Clinical ink's growth

WINSTON-SALEM, N.C., Oct. 19, 2026 /PRNewswire/ -- Clinical ink, a global clinical trial technology company, today announced investments from Ardan Equity ("Ardan"), a private equity firm specializing in healthcare technology, through Ardan Equity Fund I and from GI Partners ("GI"), a leading private investment firm that has partnered with the company since 2020, through GI Partners Fund VI. Existing investors, including GI Partners Fund V, realized a full exit of their prior investments, and Ardan and GI Partners both invested new equity in a co-control partnership.

Clinical ink provides electronic clinical outcome assessments (eCOA), connected device and other eClinical technologies to pharmaceutical companies and contract research organizations (CROs) to capture complex clinical trial data. Its combination of configurable technology, complex endpoint expertise, and integrated device capabilities support the latest FDA requirements in clinical trials as well as the emerging era of technology-enabled clinical care.

Drawing on their complementary life sciences and healthcare technology expertise, Ardan and GI will collaborate closely with management to continue to scale the Clinical ink platform globally, pursue opportunities across clinical research and care, and deliver innovative solutions that meet the rapidly evolving needs of the industry, while maintaining the highest standards of quality and compliance.

Since GI's initial investment in 2020, Clinical ink has expanded its global footprint, market position, platform, and capabilities. During that time, the company has meaningfully grown revenue, expanded therapeutic areas, deepened preferred provider relationships with leading pharmaceutical companies, launched differentiated solutions (including GlucoseReady and SPUR), and began its expansion into clinical care disease management through the Kaitality™ application.

Dave Kreter, Managing Director and Head of Healthcare at GI Partners, said, "We are pleased with the performance of the company since our 2020 investment and the tremendous progress the company has made in expanding its customer base and strengthening its position as a leading global clinical trial technology provider. Our partnership with CEO Jonathan Goldman and the Clinical ink team, together with GI's decade-plus experience investing in the healthcare technology and pharma services space, have delivered strong results to date. Looking ahead, we believe the accelerating pace of pharma R&D, the increasing complexity in clinical trials, and the need for high-quality tech solutions will provide strong tailwinds behind Clinical ink, and we look forward to building on that success alongside Ardan as the company enters its next phase of growth."

"We're delighted to welcome Clinical ink as our inaugural investment in Ardan Equity Fund I and as our eighth platform investment since 2020. We believe Clinical ink is at a key inflection point, with a compelling platform, a growing portfolio of leading pharmaceutical sponsors, and a strong path towards further expanding its footprint across the industry," said Noah Lewis, Managing Partner at Ardan Equity. "Its differentiated technology, endpoint expertise, and patient-centric approach make Clinical ink a compelling partnership for Ardan and an ideal fit for our investment thesis, our healthcare and life sciences technology sector specialist strategy, and our portfolio. We look forward to partnering with GI, Jonathan Goldman and the Clinical ink management team as we seek to accelerate the company's next phase of growth."

Jonathan Goldman, MD, Chief Executive Officer of Clinical ink, stated, "The management team and I are excited to work closely with Ardan and GI Partners to drive the next chapter of Clinical ink's evolution. We were impressed with Ardan's expertise, capabilities, and commitment to our company's growth. Our team is delighted that our long-term investors at GI remain with us given their longstanding experience with the company and its growth plans. The new investment by Ardan and GI represents a very positive development for our customers, the patients they serve, and the Clinical ink team."

Centerview Partners LLC and Guggenheim Securities, LLC served as financial advisors and Ropes & Gray LLP served as legal advisor to Clinical ink and GI Partners Fund V. Goodwin Procter LLP served as legal advisor to Ardan and Kirkland & Ellis LLP served as legal advisor to GI Partners Fund VI. Raymond James also acted as financial advisor to Ardan and GI Partners Fund VI. Ernst & Young, LLP acted as financial advisor to Ardan.

About Ardan Equity

Founded in 2019, Ardan Equity is a private equity firm exclusively focused on the healthcare and life sciences technology ecosystem. Ardan partners collaboratively with founders and management teams to accelerate growth and create differentiated platforms. As founders, operators, and investors, the Ardan team has built many of the defining healthcare and life sciences technology companies across life sciences, payer, provider and employer markets. Ardan utilizes its operator-investor approach and trusted network to help drive risk-adjusted performance. The firm invests capital on behalf of leading institutional investors globally and is headquartered in Palm Beach, Florida. For more information, please visit www.ardanequity.com.

About GI Partners

Founded in 2001, GI Partners is a private investment firm with over 180 employees and offices in San Francisco, New York, Dallas, Chicago, Greenwich, Scottsdale, and London. The firm has raised more than $50 billion and invests on behalf of leading institutional investors around the world through its private equity, real estate, and data infrastructure strategies. The private equity team invests primarily in companies in the healthcare, services, and software sectors. The real estate team focuses primarily on technology and healthcare properties as well as other specialized types of real estate. The data infrastructure team invests primarily in hard asset infrastructure businesses underpinning the digital economy. For more information, please visit www.gipartners.com.

About Clinical ink

Clinical ink is a global clinical technology company that helps pharmaceutical companies capture patient and clinical data through electronic clinical outcome assessments (eCOA) and connected device solutions in complex clinical trials. Its configurable technology platform combines deep endpoint expertise with integrated device capabilities to support increasingly sophisticated studies and generate regulatory-grade data. Clinical ink is headquartered in Winston-Salem, North Carolina with offices in Iowa, Pennsylvania and Copenhagen Denmark. For more information, please visit www.clinicalink.com.

Media Contacts

Ardan Equity

Urmi Jain, Investor Relations

[email protected]

GI Partners

Chris Tofalli, Public Relations

[email protected]

Emily Kuan, Investor Relations

[email protected]

SOURCE Clinical ink

Share this article

Half of patients with the hormonal disorder, which raises risk of heart attack, stroke and kidney disease, may be undiagnosed under current screening thresholds

SECAUCUS, N.J., Oct. 19, 2026 /PRNewswire/ -- A new study finds that current medical guidelines may inadvertently lead to under-diagnosis of primary aldosteronism (PA), a hormonal disorder associated with hypertension that can significantly raise a person's risk of heart attack, stroke and kidney disease if left untreated.

Published in the journal Hypertension, a publication of the American Heart Association, the findings suggest that changing the diagnostic threshold for PA would double the detection rate, identifying thousands of high-risk patients who may otherwise be undiagnosed and untreated.

Researchers from Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, Mass General Brigham, Harvard Medical School and the University of Texas Southwestern Medical School conducted the study, based on deidentified results of lab tests performed by Quest on over 60,449 patients in the United States.

Primary aldosteronism occurs when the adrenal glands produce too much aldosterone, a hormone that helps regulate sodium and potassium in the blood. High blood pressure is a defining feature of the condition, though affected individuals may have other common symptoms like headaches or muscle cramps. If left untreated, several complications can occur.

In 2025, the Endocrine Society published guidelines that recommend screening for PA for all patients with high blood pressure and included criteria for diagnosing PA. However, the new study suggests these guidelines are "overly restrictive," with laboratory cutoffs for aldosterone levels that detect only the most advanced cases of the disease. The guideline update also recommends plasma renin activity (PRA), a blood test that measures the conversion of renin in the kidneys, as the initial screening test.

When the researchers applied the 2025 criteria (PRA ≤1 ng/mL/h, aldosterone levels ≥7.5 ng/dL, ARR > 15) to the patient cohort, only 13.0% of individuals were identified as positive for PA. However, a broader, "permissive" set of criteria (PRA ≤1 ng/mL/h, aldosterone levels >5 ng/dL, without an ARR requirement) applied to the same cohort identified approximately twice as many patients, 26.2%, with PA. Additionally, clinical conditions consistent with PA such as hypertension, hypokalemia, and atrial fibrillation (based on insurance claim billing), were enriched among patients categorized as positive for PA by the more permissive laboratory cutoffs.

Among patients identified by the more permissive criteria, a PRA score of 0.5 ng/mL/hr had 1.27 times higher odds of having hypertension compared to those with a higher (or normal) PRA (P 0.0001). Patients with a PRA of 0.25 ng/mL/hr had 2.62 times higher odds of having atrial fibrillation (P = 0.0032). 79.0% of the additional patients identified by permissive criteria were missed by the 2025 criteria because they had aldosterone levels between 5 and 7.5 ng/dL, below the ES cutoff, while approximately one in five had aldosterone levels that met the ES criteria but did not meet the ARR threshold.

The findings suggest the 2025 guidelines may guide physicians to identify only the more advanced forms of the disease and that primary aldosteronism should be viewed as a spectrum rather than a positive or negative diagnosis of disease. Earlier detection using more relaxed diagnostic criteria may help clinicians identify and intervene with care with potential to prevent long-term cardiovascular complications.

"Our findings demonstrate that current international clinical guidelines for diagnosing primary aldosteronism are optimized to identify advanced disease but may be less sensitive for earlier or milder forms of PA," said lead author Marco Marcelli, MD, a board-certified endocrinologist and Medical Director at Quest Diagnostics. "Some patients with PA spend years on a diagnostic journey before learning their hypertension, headaches and other symptoms are due to a highly treatable condition. More expansive screening and diagnostic criteria may help the medical community to quickly identify these individuals hiding in plain sight before irreversible heart damage and other adverse outcomes have occurred."

The study's strengths include its large patient cohort and its limitations include its retrospective design and lack of confirmatory testing.

Primary aldosteronism is a serious condition that affects as many as 5-10% of adults with high blood pressure. Up to 25-30% of patients with hypertension may be diagnosed with PA if the criteria identified by the Quest group will eventually be confirmed in prospective studies. High blood pressure is widely prevalent in the U.S., affecting nearly half of all adults (almost 120 million individuals). For many years, PA was considered uncommon; however, a 2024 study published in Hypertension by researchers at Quest Diagnostics shows PA is likely under-detected.

About Quest Diagnostics

Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com

SOURCE Quest Diagnostics

Share this article

LAS VEGAS, Oct. 19, 2026 /PRNewswire/ -- NICHOLAS AIR will return to the 2026 National Business Aviation Association Business Aviation Convention & Exhibition (NBAA-BACE) in Las Vegas, Nevada from October 19-22. The conference serves as the largest annual gathering for the business aviation community and brings together industry pioneers, flight department leadership, and operational experts from across the globe.

A centerpiece of the company's presence at this year's convention will be an exclusive fireside chat featuring NICHOLAS AIR Founder and Chief Executive Officer, Nicholas Correnti. The session is scheduled for Tuesday, October 20th at 2:15 PM on the Horizon Stage.

During the discussion, Correnti will provide strategic insight into the evolving operational challenges in private aviation. Key topics will address navigating OEM part supply disruptions, Engine OEM program shortfalls, and working through antiquated regulatory bottlenecks.

"NBAA-BACE continues to be a key event for innovation and leadership in our industry and provides a vital forum to address the operational challenges that operators face today," said Nicholas Correnti, Founder and CEO of NICHOLAS AIR. "From maintaining fleet reliability amid OEM shortfalls to navigating regulatory barriers, our priority continues to be executing at the highest standard for our Members. We look forward to engaging with our peers and sharing our approach to help our industry evolve."

Throughout the convention, attendees, prospective flight operations personnel, and corporate partners are invited to connect with NICHOLAS AIR representatives to discuss operational innovations, pilot career pathways, and the company's dedicated approach to safety and aircraft management.

About NICHOLAS AIR

NICHOLAS AIR is the Standard of private aviation in the United States, distinguished by owning and operating the industry's most exclusive fleet for its national Members. For nearly 30 years, the company has remained true to an authentic heritage built on uncompromising quality, consistency, and trust—delivering an elevated private travel experience for its Private Jet Card Members and Fractional Owners. Every day, every flight, NICHOLAS AIR continues to define the premium standard of Part 135 operators.

Media Contact:

Paxton Song

[email protected]

www.nicholasair.com

SOURCE Nicholas Air

Share this article

Breaking the Limits, Generation After Generation: The HONOR X Series Durability Legacy

From reinforced glass to two Guinness World Records — how every HONOR X Series phone broke the limit of its class, and how HONOR X9e Pro breaks nearly all of them at once.

DUBAI, UAE, Oct. 19, 2026 /PRNewswire/ -- Durability has become one of the most recognisable signatures of HONOR's X Series. But that reputation wasn't built by one tough phone, it was built by a pattern. Generation after generation, HONOR hasn't just made the X Series tougher. It has made each new model the phone that broke the limit of what a device in its class was expected to survive: independently certified, put through record-breaking public tests, and, twice now, enshrined in the Guinness Book of World Records. Generation after generation, the X Series has become known for pushing beyond what a smartphone in its class is expected to withstand, earning its reputation as a truly unbreakable series.

From reinforced displays to whole-device protection, from drop resistance to water, dust and battery endurance, the X Series story is one of continuously raising — and breaking — the benchmark. With HONOR X9e Pro, that legacy reaches its most advanced chapter yet: a phone that doesn't break one limit at a time, but several of them at once.

X9a: Breaking the Limit on What a Display Could Survive

The story starts with the display, because that's traditionally where phones fail first.

HONOR X9a introduced deeply reinforced 0.65mm glass capable of withstanding more than 900MPa of stress — at a time when most phones in its class treated the screen as the weak point rather than an engineered one. HONOR tested the device through marble drops, squeezing, rolling and steel-ball impact, establishing early on that resistance to everyday damage would become the defining trait of the X Series. HONOR X9a was known the smartphone with the strongest display at that time.

X9b: The First Phone in the Industry to Prove It

HONOR X9b turned that philosophy into a much stronger, and independently verified, proposition. Its HONOR Ultra-Bounce Anti-Drop technology delivered 360-degree whole-device protection, reinforcing not just the screen but the frame and internal compartments, and supported drop resistance from heights of up to 1.5 metres.

Crucially, this generation is where the claims stopped being HONOR's alone. X9b became the first smartphone in the entire industry to receive Switzerland's SGS Five-Star Overall Drop Resistance Certification, the moment durability shifted from something HONOR claimed to something that could be externally tested, scored and verified.

X9c: Breaking the Limit on Paper Then in Front of 264 People

X9c raised the benchmark again, expanding protection to cover drop, water and scratch resistance, with certified drop resistance climbing to 2 metres. It became the world's first smartphone to achieve SGS's Five-Star Comprehensive Reliability Certification — a shift from protecting individual components to certifying the reliability of the whole device.

Then HONOR took that confidence out of the lab. On 6 January 2025, 264 people simultaneously dropped HONOR X9c smartphones screen-first from shoulder height during a launch event in Manila, Philippines. Every single device counted in the attempt survived, earning HONOR Philippines an official Guinness World Records title for the Most People Performing a Mobile Phone Drop Test Simultaneously, the first time the X Series legacy was written into the record books.

X9d: Breaking the Height Limit Altogether

X9d pushed the ambition further still, adding a six-layer drop-resistant structure, tougher water and dust protection up to IP69K with 30 minutes of submersion at 1.5 metres, and a substantially larger battery to back up its "Unbreakable AI Smartphone" positioning. It became the first phone to hold both the SGS Triple-Resistant Premium Performance Certification and the SGS 5-Star Comprehensive Reliability Certification at the same time.

And then it went after the biggest record yet. In September 2025, HONOR X9d survived an intact free fall from 6.133 metres under controlled testing conditions — more than four times the drop height X9b had been certified for just two generations earlier — earning a second Guinness World Records title for the Highest Drop of a Smartphone.

HONOR X9e Pro: Where the Legacy Breaks Every Limit at Once

Every generation before it broke one limit at a time — a height, a certification, a record. HONOR X9e Pro is where that pattern changes: durability is now engineered as one connected system, and it pushes past the previous limit on nearly every axis simultaneously, rather than picking a single headline number to chase.

Arch-shaped impact-dispersal structures around the corners and perimeter, supported by high-strength metal reinforcement in the mid-frame, redirect the force of a fall away from the display and mainboard — supporting drops from up to 3 metres onto smooth marble and earning SGS Five-Star certification for Drop Resistance in Harsh Scenarios. A continuous PUR shear-resistant adhesive around the display edges delivers approximately 10 times the shear resistance[1] of a conventional backing adhesive, reducing movement between display and frame on impact.

On the water and dust side, X9e Pro carries IP68, IP69 and IP69K ratings together, tested through immersion at depths of up to 10 metres, roughly 100,000 water-exposure cycles and a 24-hour continuous salt-spray test. It's also rated to withstand hot-water exposure up to 85°C[2], an industry-leading heat-resistance claim in its class.

And the battery breaks its own limit too: an 11,000mAh fourth-generation silicon-carbon battery — 2,700mAh larger than the previous generation and the largest in its category — while the phone stays approximately 8.08mm thin and around 203g. Toughness, this time, doesn't come at the cost of the everyday smartphone experience.

A Legacy Defined by Breaking the Bar, Not Just Raising It

Each X Series generation didn't just replace the last one. It had to prove, independently and often publicly, that it had broken the limit the previous phone set. That is the legacy HONOR X9e Pro inherits — and, on nearly every front, the one it now extends.

[1] Data comes from HONOR labs.

[2] Data comes from HONOR labs.

SOURCE HONOR

Share this article